The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in ...

Pulses of light and sound seem to have beneficial effects. But some argue it is too soon to market experimental devices.

Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's ...

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version ...

An FDA-approved synthetic version of THC (the main ingredient in cannabis) reduces agitation in patients with Alzheimer's ...

The time of day when blood is taken can affect the results of tests for diagnosing dementia, according to new research led by ...

An FDA-approved synthetic THC significantly reduces agitation in Alzheimer's patients, improving treatment outcomes and ...

“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the ...

Managing dementia in the complex landscape of neurological disorders stands out as a formidable challenge, affecting millions ...

Researchers suggest that the way Alzheimer's reshapes our brains is as unique as our fingerprints, challenging long-held ...

WASHINGTON, DC / ACCESSWIRE / October 1, 2024 / Boosting research investment into the health and wellbeing of adults with Down syndrome would ...